Table 4.

Adverse events.

Adverse events (n, %)	All patients (n = 35)	rhTPO group (n = 20)	Non-rhTPO group (n = 15)	p-value
Infection rate	4 (11.4%)	2 (10.0%)	2 (13.3%)	0.980
Drug-related liver injury	5 (14.3%)	3 (15.0%)	2 (13.3%)	0.991
Drug-related renal injury	2 (5.7%)	1 (5.0%)	1 (6.7%)	0.979
Fatigue	3 (8.6%)	2 (10.0%)	1 (6.7%)	0.809
Gastrointestinal disorders (diarrhea, nausea, and abdominal pain)	7 (20.0%)	4 (20.0%)	3 (20%)	1.000
Intracranial hemorrhage	1 (2.6%)	1 (5.0%)	0 (0%)	0.999

rhTPO, recombinant human thrombopoietin.